Prognostic implication of PD‐L1 polymorphisms in non‐small cell lung cancer treated with radiotherapy

To investigate the impact of programmed death‐ligand 1 (PD‐L1) polymorphisms on the prognosis of non‐small cell lung cancer (NSCLC) patients treated with curative radiotherapy.

[1]  T. Nakano,et al.  Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment , 2020, International Journal of Clinical Oncology.

[2]  D. Aoki,et al.  Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma , 2019, Journal of gynecologic oncology.

[3]  F. Tanaka,et al.  Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer , 2019, British Journal of Cancer.

[4]  I. Melero,et al.  Immune mechanisms mediating abscopal effects in radioimmunotherapy , 2019, Pharmacology & therapeutics.

[5]  A. Shibata,et al.  Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy , 2019, Front. Oncol..

[6]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[7]  Arnaud Boyer,et al.  Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. , 2018, Journal of thoracic disease.

[8]  Kyung-Hee Kim,et al.  Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma. , 2017, Human pathology.

[9]  M. Kokubo,et al.  Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients , 2017, Scientific Reports.

[10]  Young Hak Kim,et al.  Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients , 2017, Scientific Reports.

[11]  Joël Castelli,et al.  The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership. , 2017, Critical reviews in oncology/hematology.

[12]  J. Park,et al.  Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer. , 2017, Gene.

[13]  M. Mino‐Kenudson.  Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? , 2016, Cancer biology & medicine.

[14]  J. Park,et al.  PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy , 2016, Scientific Reports.

[15]  D. Lin,et al.  Genetic alteration profiling of patients with resected squamous cell lung carcinomas , 2016, Oncotarget.

[16]  K. Azuma,et al.  Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. , 2016, European journal of cancer.

[17]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[18]  I. Stratford,et al.  Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. , 2014, Cancer research.

[19]  S. Demaria,et al.  Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death , 2014, Oncoimmunology.

[20]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[21]  R. Weichselbaum,et al.  Radiation as an immune modulator. , 2013, Seminars in radiation oncology.

[22]  C. Mu,et al.  High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation , 2011, Medical oncology.

[23]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[24]  A. Mackensen,et al.  Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion , 2007, Cancer Immunology, Immunotherapy.

[25]  M. Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[26]  P. Donnelly,et al.  A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.

[27]  Frank C. Detterbeck,et al.  The Eighth Edition Lung Cancer Stage Classification , 2017, Chest.

[28]  Sin-Ho Jung,et al.  Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. , 2016, European journal of cancer.